Results 91 to 100 of about 9,615 (165)
A guide to transcriptional cyclin‐dependent kinases in cancer
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin +2 more
wiley +1 more source
David L Tucker, Simon A Rule Department of Haematology, Plymouth Hospitals NHS Trust, Plymouth, UK Abstract: Although chemo-immunotherapy remains at the forefront of first-line treatment for mantle cell lymphoma (MCL) and chronic lymphocytic leukemia ...
Tucker DL, Rule SA
core
Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL) [PDF]
The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib is a new targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib is given orally on a continuous schedule and induces durable remissions in the majority of CLL patients ...
Burger, Jan A +2 more
core +1 more source
Lipid‐derived reactive electrophile molecules (REMs) are generated from fatty acids through lipoxygenase or cyclooxygenase‐assisted catalysis, or free radical‐induced lipid peroxidation events. REMs so‐produced covalently modify nearby protein‐cysteines, and in the case of ‘first responder’ proteins, can trigger gain‐of‐function signaling with context ...
Marcus J. C. Long +2 more
wiley +1 more source
We present 12 cases of MCL with predominant extranodal disease, with MALToma‐like presentation, including immunogenetic profile and mutational landscape analysis, based on targeted NGS approach. Our data seem to confirm that this subset shows a more indolent clinical course than CN‐MCL and suggests that different genetic pathways may be involved.
Marco Lucioni +16 more
wiley +1 more source
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib [PDF]
BackgroundIbrutinib is a Bruton tyrosine kinase inhibitor and is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) in frontline and relapsed/refractory settings.
Alessandra Ferrajoli +19 more
core +1 more source
Abstract Autoimmune haemolytic anaemia is a rare immune‐mediated disorder leading to accelerated red cell destruction and anaemia. There is considerable clinical heterogeneity, with some patients barely requiring intervention, while others experience fulminant haemolysis and experience mortality rates as high as 30% with severe anaemia and end‐organ ...
Philip Choi +9 more
wiley +1 more source
Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab
Rituximab‐refractory pemphigus vulgaris is driven by B‐cell repopulation, plasma‐cell persistence, IgG4 autoantibodies and anti‐drug antibodies. This review evaluates five emerging targeted classes acting at successive steps of disease: next‐generation anti‐CD20 antibodies, DSG3‐CAAR T cells, BTK inhibitors, BAFF/APRIL inhibitors and FcRn antagonists ...
Rhea Ahuja, Dedee Murrell
wiley +1 more source
ABSTRACT Background Covalent Bruton tyrosine kinase inhibitors (cBTKis) are standard first‐line (1L) therapies for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In clinical trials, second‐generation (2G) cBTKis demonstrated better tolerability than ibrutinib, particularly regarding cardiotoxicity; however, real‐world evidence on ...
John M. Burke +10 more
wiley +1 more source
ABSTRACT Introduction Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia. Methods We retrospectively evaluated 679 zanubrutinib‐treated patients across 52 Italian centers, with 354 historical ibrutinib‐treated controls. Shanafelt AF scores were assessed.
Andrea Visentin +92 more
wiley +1 more source

